Skip to Content

Amyvid Approval History

FDA Approved: Yes (First approved April 6, 2012)
Brand name: Amyvid
Generic name: florbetapir F 18
Dosage form: Injection
Company: Eli Lilly and Company and Avid Radiopharmaceuticals, Inc.
Treatment for: Diagnosis and Investigation

Amyvid (florbetapir F 18) is a radioactive diagnostic agent used for brain imaging of beta-amyloid plaques in patients who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

Development History and FDA Approval Process for Amyvid

DateArticle
Apr  9, 2012Approval FDA Approves Amyvid (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
Mar 18, 2011Lilly and Avid Receive Complete Response Letter from FDA for Amyvid (florbetapir F 18 injection)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide